| | Variables | Infected
| Control
|
| | Age range (mths) | 24–180 | 24–180 | | Age group | | | | 18–59 mths (, %) | 43 (61.4) | 43 (61.4) | | 60–119 mths (, %) | 21 (30.0) | 22 (31.4) | | 120–227 mths (, %) | 6 (8.6) | 5 (7.1) | | Mean age ± SD (mths) | 58.4 ± 37.8 | 58.01 ± 38.1 | | Gender (M versus F) | 40 versus 30 | 39 versus 31 |
| |
*Social class (, %) | | | | I | — | 9 (112.9) | | II | 14 (20.0) | 19 (27.1) | | III | 16 (22.9) | 15 (21.4) | | #IV | 27 (38.9) | 13 (18.6) | | V | 13 (18.6) | 14 (20.0) |
| | Anthropometry scores | | | | #Median WAZ (25, 75) male | −0.18 (−0.62, 0.59) | −0.35 (−0.54, 0.38) | | Median WAZ (25, 75) female | −0.53 (−0.81, 0.36) | −0.51 (−0.66, −0.15) | | Median HAZ (25, 75) male | −0.13 (−0.67, 0.70) | −0.22 (0.68, 0.79) | | Median HAZ (25, 75) female | −0.61 (−0.88, 0.46) | −0.53 (−0.83, 0.18) | | #Median WHZ (25, 75) male | −1.34 (−2.29, −0.21) | −0.34 (−0.89, 0.09) | | #Median WHZ (25, 75) female | −1.13 (−1.87, −0.44) | −0.32 (−1.11, 0.00) |
| |
#Mean ± SD serum albumin (g/L) | 3.2 ± 0.7 | 4.0 ± 0.5 | |
#Mean ± SD CD4 count (cells/mL) | 611.4 ± 444.5 | 1388.2 ± 556.5 | |
#Mean ± SD CD4 % (%) | 18.8 ± 13.2 | 35.4 ± 4.4 |
| | Clinical stage (, %) | | | | 1 | 8 (11.4) | — | | 2 | 15 (21.4) | — | | 3 | 31 (44.3) | — | | 4 | 16 (22.9) | — |
| | Immunological stage (%) | | | | Not significant immunosuppression | 4 (5.7) | — | | Mild significant immunosuppression | 15 (21.4) | — | | Advanced significant immunosuppression | 18 (25.7) | — | | Severe significant immunosuppression | 33 (47.1) | — |
| | Serum micronutrient (mean ± SD) | | | | #Zinc (g/dL) | 66.99 ± 16.7 | 82.78 ± 25.8 | | #Vitamin C (g/dL) | 0.41 ± 0.29 | 0.78 ± 0.28 | | #Selenium (g/dL) | 7.26 ± 0.2 | 9.81 ± 1.6 |
| | Low albumin [ (%)] | 40 (57.1) | 7 (14.9) |
| | Micronutrient deficiency (%) | | | | #Zinc deficient | 54 (77.1) | 31 (44.3) | | #Selenium deficient | 50 (71.4) | 13 (18.6) | | #Vitamin C deficient | 49 (70.0) | 11 (15.7) |
|
|
